Leidos (LDOS) Secures $318M Contract for Military Health System
Leidos (LDOS) won a $318M contract from the Defense Health Agency for MHS GENESIS support. LDOS trades at $119.70, 30.7% below its GF Value™ of $172.78, with a GF Score™ of 85/100. Insiders sold $3.2M in shares over 12 months. The company serves government clients, with revenue from long-term contracts.
How this was made
The 30-second read
Why it matters
The $318 M award expands Leidos' backlog, improves revenue visibility through 2028, and may trigger analyst upgrades, supporting a bullish bias.
Market read
A material contract win for a mid‑cap defense IT firm, offering a fresh catalyst for price appreciation and sector sentiment.
What to watch
Execution risk on complex system integration and possible future competition for follow‑on contracts.
Background
Leidos (LDOS) is a U.S. science, engineering and IT firm serving defense, intelligence and homeland‑security agencies. The Defense Health Agency's MHS GENESIS is the DoD's flagship electronic health‑record platform.
Ticker impact
Leidos secured a $317.99 million firm‑fixed‑price contract from the Defense Health Agency to support MHS GENESIS system reintegration, software licensing and hosting through Jan 2028.
potential upside as investors price in the new revenue and longer‑term backlog
A $318 M award to a mid‑cap defense IT provider is material and newly disclosed, providing fresh upside catalysts.
Market effects
Strengthens the defense and government‑IT services sector, highlighting demand for electronic health‑record solutions.
Positive for U.S. defense contractors and federal‑spending outlook.
Limited to firms with comparable government‑IT contracts; modest global ripple.
Counterpoint
The contract may be offset by slower civilian IT growth and potential budget cuts, limiting upside.
Key entities
- companyLeidos Holdings Inc.
U.S. defense and IT services provider, ticker LDOS.
- government_agencyDefense Health Agency
U.S. DoD agency overseeing military health services.
